Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Apter

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
International Journal of Cancer|November 19, 2019
Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trialMatti Lehtinen, Dan Apter, Tiina Eriksson, et al.
Contraception|June 21, 2005
Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimenEdith Weisberg, Vivian Brache, Francisco Alvarez, et al.
Contraception|June 21, 2005
Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimenIan S Fraser, Edith Weisberg, Vivian Brache, et al.
Contraception|November 17, 2009
Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trialAlexander Teichmann, Dan Apter, Janusz Emerich, et al.
BMC Research Notes|July 12, 2014
Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot studyProscovia B Namujju, Emma Pajunen, Aline Simen-Kapeu, et al.
Expert Review of Vaccines|February 24, 2016
Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseasesS Rachel Skinner, Dan Apter, Newton De Carvalho, et al.
The Journal of Infectious Diseases|June 21, 2023
Incidence of Cytomegalovirus Primary and Secondary Infection in Adolescent Girls: Results From a Prospective StudyRobert Paris, Dan Apter, Suresh Boppana, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2005
A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraceptionCathy J Hay, Brian M Brady, Michael Zitzmann, et al.
Human Vaccines & Immunotherapeutics|November 15, 2016
Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trialMatti Lehtinen, Tiina Eriksson, Dan Apter, et al.
Vaccine|January 17, 2015
Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trialMatti Lehtinen, Dan Apter, Iacopo Baussano, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
International Journal of Cancer|November 19, 2019
Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community-randomized trialMatti Lehtinen, Dan Apter, Tiina Eriksson, et al.
Contraception|June 21, 2005
Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimenEdith Weisberg, Vivian Brache, Francisco Alvarez, et al.
Contraception|June 21, 2005
Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimenIan S Fraser, Edith Weisberg, Vivian Brache, et al.
Contraception|November 17, 2009
Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trialAlexander Teichmann, Dan Apter, Janusz Emerich, et al.
BMC Research Notes|July 12, 2014
Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot studyProscovia B Namujju, Emma Pajunen, Aline Simen-Kapeu, et al.
Expert Review of Vaccines|February 24, 2016
Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseasesS Rachel Skinner, Dan Apter, Newton De Carvalho, et al.
The Journal of Infectious Diseases|June 21, 2023
Incidence of Cytomegalovirus Primary and Secondary Infection in Adolescent Girls: Results From a Prospective StudyRobert Paris, Dan Apter, Suresh Boppana, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2005
A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraceptionCathy J Hay, Brian M Brady, Michael Zitzmann, et al.
Human Vaccines & Immunotherapeutics|November 15, 2016
Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trialMatti Lehtinen, Tiina Eriksson, Dan Apter, et al.
Vaccine|January 17, 2015
Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trialMatti Lehtinen, Dan Apter, Iacopo Baussano, et al.
Pageof 9